Drugs / LCB02A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07460375 | Aug 2026 → Feb 2030 expected | cancer | LigaChem Biosciences, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCB02A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07460375 ↗ |
| Modality | Monoclonal antibody | “CLDN18.2-directed human monoclonal antibody (Ab)” NCT07460375 ↗ |
| Target | CLDN18 | “CLDN18.2-directed human monoclonal antibody (Ab)” NCT07460375 ↗ |